XML 75 R46.htm IDEA: XBRL DOCUMENT  v2.3.0.11
FAIR VALUE DISCLOSURES (Details 2) (USD $)
In Thousands
6 Months Ended
Jun. 30, 2011
Gemin X Pharmaceuticals | Contingent consideration (liability)
 
Liabilities measured on a recurring basis using unobservable inputs (Level 3)  
Net transfer in to Level 3 (new transactions) $ (97,111)
Unrealized gains/(losses) included in earnings (932)
Balance at the end of the period (98,043)
Ception | Contingent consideration (liability)
 
Liabilities measured on a recurring basis using unobservable inputs (Level 3)  
Balance at the beginning of the period (102,942)
Unrealized gains/(losses) included in earnings (2,688)
Balance at the end of the period (105,630)
BDC | Contingent consideration (liability)
 
Liabilities measured on a recurring basis using unobservable inputs (Level 3)  
Balance at the beginning of the period (32,266)
Unrealized gains/(losses) included in earnings (781)
Balance at the end of the period (33,047)
ChemGenex Pharmaceuticals Limited | Convertible note securities
 
Assets measured on a recurring basis using unobservable inputs (Level 3)  
Balance at the beginning of the period 9,885
Unrealized gains/(losses) included in earnings 5,115
Conversion of Convertible Notes to Equity (Transfer Out) (15,000)
Letter Agreement Derivative Instrument
 
Liabilities measured on a recurring basis using unobservable inputs (Level 3)  
Unrealized gains/(losses) included in earnings (22,078)
Balance at the end of the period $ 22,078